Moreover, according to the median expression of CD248, the overall survival (OS) rate of RCC patients in the CD248 high-expression group at 5 years was 57.5%, compared with 74.9% for the low-expression group (p < 0.001, Figure 1C). This evidence concerns the gene CD248 and renal cell carcinoma.